XAGE vs HIMS vs MGRX vs WELL vs GDRX

For growth investors, Hims & Hers Health, Inc.

(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -15. 8% for Mangoceuticals, Inc. (MGRX). GoodRx Holdings, Inc. (GDRX) offers the better valuation at 33. 3x trailing P/E (9. 0x forward), making it the more compelling value choice. Analysts rate Welltower Inc. (WELL) a "Buy" — based on 34 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, GoodRx Holdings, Inc.

(GDRX) is the cheapest at 33. 3x versus Welltower Inc. at 153. 3x. On forward P/E, GoodRx Holdings, Inc. is actually cheaper at 9. 0x.

Over the past 5 years, Welltower Inc.

(WELL) delivered a total return of +202. 3%, compared to -99. 9% for Longevity Health Holdings Inc. (XAGE). Over 10 years, the gap is even starker: WELL returned +223. 1% versus XAGE's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Welltower Inc.

(WELL) is the lower-risk stock at 0. 13β versus Hims & Hers Health, Inc. 's 2. 40β — meaning HIMS is approximately 1707% more volatile than WELL relative to the S&P 500. On balance sheet safety, Mangoceuticals, Inc. (MGRX) carries a lower debt/equity ratio of 2% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Hims & Hers Health, Inc.

(HIMS) is pulling ahead at 59. 0% versus -15. 8% for Mangoceuticals, Inc. (MGRX). On earnings-per-share growth, the picture is similar: GoodRx Holdings, Inc. grew EPS 104. 1% year-over-year, compared to -11. 5% for Welltower Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Welltower Inc.

(WELL) is the more profitable company, earning 8. 8% net margin versus -206. 1% for Longevity Health Holdings Inc. — meaning it keeps 8. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GDRX leads at 13. 4% versus -99. 3% for XAGE. At the gross margin level — before operating expenses — XAGE leads at 87. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, GoodRx Holdings, Inc.

(GDRX) trades at 9. 0x forward P/E versus 78. 4x for Welltower Inc. — 69. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HIMS: 15. 6% to $29. 67.

In this comparison, MGRX (100.

0% yield), WELL (1. 3% yield) pay a dividend. XAGE, HIMS, GDRX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Welltower Inc.

(WELL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 13), 1. 3% yield, +223. 1% 10Y return). Longevity Health Holdings Inc. (XAGE) carries a higher beta of 1. 86 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (WELL: +223. 1%, XAGE: -99. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (XAGE (Healthcare) and HIMS (Healthcare) and MGRX (Healthcare) and WELL (Real Estate) and GDRX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: XAGE is a small-cap quality compounder stock; HIMS is a small-cap high-growth stock; MGRX is a small-cap income-oriented stock; WELL is a mid-cap high-growth stock; GDRX is a small-cap quality compounder stock. MGRX, WELL pay a dividend while XAGE, HIMS, GDRX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.